The Medicines Patent Pool (MPP) warmly welcomes the successful conclusion of negotiations on the WHO Pandemic Agreement.
We are encouraged that many provisions of the agreement focus on supporting sustainable and geographically diversified local production through licensing, and technology transfer. These are areas where MPP has demonstrated practical impact, including through the mRNA Technology Transfer Programme we co-lead with WHO and our licensing of therapeutics to expand access in low- and middle-income countries.
We also welcome the focus on embedding access conditions in publicly funded R&D and procurement, which supports timely and more equitable access.
As countries move to adopt and operationalize this historic agreement, MPP stands ready to work with WHO and its Member States to support its implementation.